Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Context Therapeutics Inc (NQ: CNTX )

1.370 UNCHANGED
Streaming Delayed Price Updated: 3:49 PM EDT, Apr 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 95
Open 1.370
Bid (Size) 1.330 (1)
Ask (Size) 1.410 (2)
Prev. Close 1.370
Today's Range 1.370 - 1.370
52wk Range 0.4703 - 1.690
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
Important Regulatory Milestone Supports Next Phase of CTIM-76 Development 
From Context Therapeutics Inc.
Via GlobeNewswire
CNTX Stock Earnings: Context Therapeutics Misses EPS for Q4 2023
CNTX stock results show that Context Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace

Performance

YTD
+10.48%
+10.48%
1 Month
N/A
N/A
3 Month
+33.01%
+33.01%
6 Month
+33.01%
+33.01%
1 Year
+140.35%
+140.35%

More News

Read More
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update
Via News Direct
Why Quanex Building Products Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Constellation Energy, Battalion Oil And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76
From Context Therapeutics Inc.
Via GlobeNewswire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why AERWINS Technologies Shares Are Trading Higher By Around 90%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
From Context Therapeutics Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 11, 2023
Via Benzinga
Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update
Via TheNewswire.com
Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Context Therapeutics to Participate in Two August 2023 Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
ASCO 2023 – Claudin 6 Makes A Splash In Ovarian Cancer
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.